Who We Are

Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs.

Our Work

Reneo is initially developing REN001 in two rare genetic diseases that typically present with myopathy: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).


We completed a Phase 1b clinical trial in patients with PMM and are currently enrolling patients in a global Phase 2b clinical trial (STRIDE Study). In addition, we conducted two exploratory Phase 1b clinical trials of REN001 in patients with LC-FAOD and McArdle disease, respectively.

Leadership Team

Meet the Reneo Executive Team!

Gregory J. Flesher

President & Chief Executive Officer

Alejandro Dorenbaum, M.D.

Chief Medical Officer

Ashley F. Hall, J.D.

Chief Development Officer

Michael P. Cruse

Chief Operating Officer

Wendy S. Johnson, MBA

Chief Business Officer

Lynn Purkins, Ph.D.

Senior Vice President of Clinical Operations

Board of Directors

With Reneo

Reneo works with investor partners to enable continued progress in our clinical development programs.


Executive Chairman

Eric Dube, Ph.D.


President & Chief Executive Officer

Paul W. Hoelscher

Ed Mathers

Bali Muralidhar

Niall O’Donnell

Stacey D. Seltzer